Molecular modeling showed that genetic fusion of the DR5-specific TRAIL variant DR5-B with SRH and iRGD peptides not only enabled the engagement of additional tumor targets, but also improved the interaction with DR5 receptor. This evidence concerns the gene TNFSF10 and neoplasm.